Physician profile
Peter Gontzes
NPI 1083897458
$10,129.29
in general payments reported to CMS, 2019-2025
23 companies · $1,984 in 2025
The $1,984 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $685 · 2021: $1,738 · 2022: $1,963 · 2023: $1,852 · 2024: $1,507 · 2025: $1,984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,289 · Education: $54.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,288.98 |
| Education | $54.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,265.62 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,717.04 | 2020-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,692.09 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $843.34 | 2019-2025 | Tezspire, Breztri |
| Optinose US, INC. | $566.49 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $460.11 | 2019-2025 | |
| Amgen INC. | $242.94 | 2022-2025 | Tezspire |
| Alk-Abello, INC | $238.41 | 2021-2023 | Grastek, Ragwitek, Odactra |
| Kaleo, INC. | $225.46 | 2020-2024 | Auvi-Q |
| Pfizer INC. | $201.32 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $114.94 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.69 | 2023-2024 | Glassia, Eohilia, Cuvitru |
| Genentech USA, INC. | $87.66 | 2019-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $74.59 | 2025 | Neffy |
| Covis Pharma Gmbh | $70.29 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $65.97 | 2023-2025 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $38.46 | 2022 | |
| Inspire Medical Systems, INC. | $24.03 | 2023 | Inspire |
| Aimmune Therapeutics, INC. | $23.92 | 2022 | |
| Biocryst US Sales Co., LLC | $22.78 | 2024 | Orladeyo |
| Merck Sharp & Dohme LLC | $17.69 | 2019 | |
| Circassia INC. | $16.05 | 2020 | |
| Neos Therapeutics, LP | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Gontzes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.